Retatrutide 1mg: Micro-Starting Dose Guide

    By Trimi Medical Team11 min read

    Retatrutide 1mg is the micro-starting dose used in the Phase 2 clinical trial to gently introduce the body to the drug's triple receptor mechanism — GLP-1, GIP, and glucagon (Jastreboff et al., NEJM 2023). At this dose, the drug's effects are subtle: mild appetite reduction, minimal GI side effects, and the beginning of metabolic receptor priming. The 1mg dose is not about producing significant weight loss — it is about laying the foundation for safe, tolerable dose escalation.

    Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Never take investigational medications outside clinical trials. Always consult a qualified healthcare provider.

    What to Expect at 1mg

    • Weight loss: Minimal to modest (1-3 lbs in the first 2-4 weeks) — this dose is primarily for acclimatization
    • Appetite: Mild reduction — most patients notice slightly less hunger, especially between meals
    • GI effects: Mild nausea in 8-12% of patients; usually brief and manageable
    • Dysesthesia: Rare at this dose (under 5%)
    • Heart rate: No clinically meaningful change at 1mg

    Why Start at 1mg?

    Starting at a micro dose gives the GI tract, cardiovascular system, and peripheral nervous system time to acclimate to three new receptor activations simultaneously. Patients who jump to higher doses without titration experience significantly more nausea, vomiting, and diarrhea. The 1mg starting dose is an investment in long-term tolerability.

    Think of it like breaking in new shoes gradually rather than running a marathon on day one. The discomfort of a slow start is far less than the discomfort of overwhelming your system.

    How Long to Stay at 1mg

    The Phase 2 protocol used 2-4 weeks at the starting dose before the first escalation. Your prescribing physician may adjust this based on your individual tolerance. If you experience significant nausea or GI effects even at 1mg, extending the starting period by 1-2 weeks can improve subsequent tolerance.

    Tips for Your First Injection

    • Choose a consistent injection day (e.g., every Monday)
    • Start hydrating well 2-3 days before your first injection
    • Have ginger chews and bland snacks on hand
    • Inject in the evening so any nausea occurs during sleep
    • Plan lighter meals for the first 2-3 days

    Start GLP-1 Treatment Today

    While retatrutide is not yet available, you can begin your weight loss journey now with proven GLP-1 medications. Trimi offers compounded semaglutide at $99/month and compounded tirzepatide at $125/month, both using gradual dose titration for optimal tolerability. Get started with Trimi.

    Frequently Asked Questions

    Will I lose weight on retatrutide 1mg?

    Some patients lose 1-3 lbs during the starting dose period, primarily from mild appetite reduction. Significant weight loss begins during dose escalation to 4mg and above.

    Can I skip the 1mg dose and start higher?

    This is not recommended. Skipping the starting dose significantly increases the risk and severity of GI side effects. Gradual titration is essential for safety and tolerability.

    What if I feel nothing at 1mg?

    This is normal and expected. The 1mg dose is a priming dose, not a therapeutic dose. Feeling minimal effects means you are on track for a smooth escalation to therapeutic doses.

    How long until I reach the full dose?

    The titration from 1mg to 12mg typically takes 12-16 weeks with gradual increases. Your physician may adjust the schedule based on your response.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading

    What's the dosing schedule for retatrutide?

    Retatrutide phase 2 TRIUMPH-1 trial (Jastreboff et al., NEJM 2023) tested 5 dose levels: 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg per week as subcutaneous injections. Phase 2 dose-escalation protocol: starting dose 2 mg/week subcutaneously once weekly, escalate every 4 weeks by approximately 2 mg until target dose is reached or tolerance limits dose increase. Maximum studied dose: 12 mg/week, which was associated with approximately 24% body-weight reduction at 48 weeks (the highest weight-loss outcome observed for any GLP-1-class medication to date). Side effects are dose-dependent — see retatrutide-se-by-dose for details. Phase 3 TRIUMPH program (ongoing 2024-2026) will refine the optimal dosing range, titration schedule, and approved dose levels for FDA approval. Likely approval scenario will follow the tirzepatide template: multiple dose strengths (e.g., 2.5, 5, 7.5, 10, 12.5, 15 mg) with 4-week titration intervals, allowing patients to find their optimal balance between efficacy and tolerability. Critical caveat: retatrutide is investigational and NOT FDA-approved as of May 2026; dosing schedules and approved doses are subject to phase 3 confirmation. Earliest possible FDA approval: 2027-2028. For weight-loss treatment now, FDA-approved tirzepatide is the closest accessible alternative with well-characterized dosing — Trimi Health offers compounded tirzepatide at $125/month annual with appropriate clinical titration via Beluga Health 50-state clinician network. Patients should NOT seek 'research peptide' retatrutide outside legitimate clinical trial enrollment.

    Phase 2: 1-12 mg/week (5 doses tested).
    Titration: starting 2 mg, escalate every 4 weeks by ~2 mg.
    Phase 3 will confirm final dosing for FDA approval.

    Key Takeaways

    • Retatrutide phase 2 dosing: 1, 2, 4, 6, 8, 12 mg/week subcutaneous injection (5 dose levels tested).
    • Phase 2 TRIUMPH-1 escalation: starting dose 2 mg/week, escalate every 4 weeks by ~2 mg until target dose reached.
    • Maximum studied dose: 12 mg/week (associated with ~24% body-weight reduction at 48 weeks).
    • Phase 3 TRIUMPH program will refine optimal dosing range and titration schedule for FDA approval.
    • Retatrutide is investigational and NOT FDA-approved as of May 2026; dosing schedules subject to phase 3 confirmation.
    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Dr. Asad Niazi, MD, MPH

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook
    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    2. Eli Lilly and Company (2025). Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration.Read Study
    3. The Endocrine Society (2024). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism.Read Study

    Was this article helpful?

    Keep Reading

    The definitive 2026 guide to retatrutide (LY3437943): mechanism of action, Phase 2 and 3 trial results, dosing, side effects, cost, availability, eligibility, and how to get started.

    Retatrutide

    Retatrutide 2mg

    Retatrutide 4mg is the first therapeutic dose — where real weight loss begins. 17.5% average weight loss at this dose alone. Expected results, side effects, and when to consider escalating.

    Retatrutide vs phentermine: 24.2% weight loss with a triple-agonist hormone vs 5-10% with a stimulant. Mechanism, side effects, duration, and why the comparison isn

    Get answers to the 30 most common questions about retatrutide, from how it works and side effects to cost, availability, eligibility, and results based on Phase 2 clinical trial data.

    Start your GLP-1 journey — from $99/mo

    Get Started